PT3002298T - Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos - Google Patents

Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos

Info

Publication number: PT3002298T
Authority: PT; Portugal
Prior art keywords: factor; methods; monoclonal antibodies; monoclonal; antibodies
Prior art date: 2007-11-21

Application number

PT151897147T

Other languages

English (en)

Inventor

Gruber Andras

Ian Tucker Erik

Raymond Hanson Stephen

Gailani David

Original Assignee

Univ Oregon Health & Science

Univ Vanderbilt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-21

Filing date

2008-11-21

Publication date

2019-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3002298(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-21 Application filed by Univ Oregon Health & Science, Univ Vanderbilt filed Critical Univ Oregon Health & Science

2019-11-20 Publication of PT3002298T publication Critical patent/PT3002298T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT151897147T 2007-11-21 2008-11-21 Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos PT3002298T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US98952307P	2007-11-21	2007-11-21

Publications (1)

Publication Number	Publication Date
PT3002298T true PT3002298T (pt)	2019-11-20

Family

ID=40568500

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT151897147T PT3002298T (pt)	2007-11-21	2008-11-21	Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos

Country Status (15)

Country	Link
US (7)	US8236316B2 (pt)
EP (2)	EP3002298B1 (pt)
JP (1)	JP2011504371A (pt)
AU (1)	AU2008326348B2 (pt)
CA (1)	CA2705851C (pt)
CY (1)	CY1122270T1 (pt)
DK (2)	DK2222707T3 (pt)
ES (2)	ES2566963T3 (pt)
HR (1)	HRP20191999T1 (pt)
HU (1)	HUE046564T2 (pt)
LT (1)	LT3002298T (pt)
PL (1)	PL3002298T3 (pt)
PT (1)	PT3002298T (pt)
SI (1)	SI3002298T1 (pt)
WO (1)	WO2009067660A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE046564T2 (hu)	2007-11-21	2020-03-30	Univ Oregon Health & Science	XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
US20110159006A1 (en) *	2008-06-19	2011-06-30	Erik Hack	Use of anti-factor xi antibodies for prevention of thrombus formation
EP2379084B1 (en)	2008-10-15	2017-11-22	Ionis Pharmaceuticals, Inc.	Modulation of factor 11 expression
LT2373691T (lt)	2008-12-18	2019-05-27	Oregon Health & Science University	Anti-fxi antikūnai ir jų panaudojimo būdai
BRPI1015236A2 (pt) *	2009-04-15	2019-09-24	Isis Pharmaceuticals Inc	métodos para modular uma resposta inflamatória, apra melhorar uma doença, distúrbio ou condição inflamatórios em um animal, para tratar um animal em risco para uma doença, distúrbio ou condição inflamatórios, para inibir a expressão de fator xi em um animal, para reduzir o risco de doença, distúrbio ou condição inflamatórios, em um animal, para tratar um animal em risco para uma doença inflamatória, e para tratar um animal tendo uma doença inflamatória, e, uso de um composto marcado para fator xi
PL2542257T3 (pl) *	2010-03-01	2018-01-31	Bayer Healthcare Llc	Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
EP2497489A1 (en) *	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CN103415301A (zh) *	2011-03-09	2013-11-27	德国杰特贝林生物制品有限公司	用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
WO2013167669A1 (en)	2012-05-10	2013-11-14	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014089493A1 (en)	2012-12-07	2014-06-12	Vanderbilt University	Antibodies against factor xii and uses thereof
JP2016505159A (ja) *	2013-02-01	2016-02-18	ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ，ＤｉｃｋｉｎｓｏｎＡｎｄＣｏｍｐａｎｙ	接触経路抑制添加剤を含む血液採集装置
WO2014135694A1 (en)	2013-03-08	2014-09-12	Csl Behring Ag	Treatment and prevention of remote ischemia-reperfusion injury
US9988443B2 (en)	2014-08-07	2018-06-05	Novartis Ag	Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
DK3177642T3 (da)	2014-08-07	2022-02-21	Novartis Ag	Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
JOP20200312A1 (ar) *	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
US11066481B2 (en) *	2015-07-23	2021-07-20	The Regents Of The University Of California	Antibodies to coagulation factor XIa and uses thereof
BR112018014810A2 (pt)	2016-01-22	2018-12-11	Merck Sharp & Dohme Corp.	anticorpos anti-fator xi de coagulação
CN109153726A (zh) *	2016-03-23	2019-01-04	普希克斯私人有限公司	抗因子xi的活性位点的单克隆抗体及其用途
TW201802121A (zh)	2016-05-25	2018-01-16	諾華公司	抗因子XI/XIa抗體之逆轉結合劑及其用途
IL315266A (en) *	2016-06-14	2024-10-01	Merck Sharp ַ& Dohme Llc	Anti-coagulation factor xi antibodies
EP3293593B1 (en) *	2016-09-12	2019-03-20	Sandvik Intellectual Property AB	Method for estimating error propagation
RU2758160C2 (ru)	2016-09-20	2021-10-26	Байер Фарма Акциенгезельшафт	Новые антитела против фактора xi и их применения
CN110325550B (zh)	2016-12-23	2024-03-08	诺华股份有限公司	因子xi抗体和使用方法
JP7110199B2 (ja) *	2016-12-23	2022-08-01	ノバルティスアーゲー	抗第ＸＩ／ＸＩａ因子抗体による処置法
US11958911B2 (en)	2017-02-10	2024-04-16	Shanghai Benemae Pharmaceutical	Anti-coagulation factor XI antibody
CN108409863B (zh) *	2017-02-10	2023-09-26	上海仁会生物制药股份有限公司	抗凝血因子xi抗体
WO2019102353A1 (en)	2017-11-22	2019-05-31	Novartis Ag	Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2019217450A1 (en)	2018-05-08	2019-11-14	Rhode Island Hospital	Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
BR112020020957B1 (pt)	2018-05-09	2022-05-10	Ionis Pharmaceuticals, Inc	Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
CN113227150B (zh) *	2018-08-09	2023-07-28	上海仁会生物制药股份有限公司	抗凝血因子xi抗体
MX2021007955A (es)	2019-01-21	2021-10-22	Aronora Inc	Nuevos anticuerpos humanizados contra el factor xi que tienen efectos anti-tromboticos y antiinflamatorios y sus usos.
EP3983448A4 (en) *	2019-06-12	2023-11-22	CSL Innovation Pty Ltd	CONJUGATES OF SOLUBLE COMPLEMENT RECEPTOR TYPE 1 VARIANTS AND USES THEREOF
KR20230035079A (ko) *	2020-07-03	2023-03-10	수조우 알파맵 씨오., 엘티디.	응고인자 xi(fxi) 결합 단백질
CN120858120A (zh) *	2022-12-30	2025-10-28	甘李药业股份有限公司	抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0216846B2 (en)	1985-04-01	1995-04-26	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
DE68921982T4 (de)	1988-06-14	1996-04-25	Cetus Oncology Corp	Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en)	1989-05-05	1992-02-26	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en)	1990-03-20	2003-02-11	Sherie L. Morrison	Chimeric antibodies with receptor binding ligands in place of their constant region
JPH09506761A (ja)	1990-11-09	1997-07-08	ステファンディー．ギリーズ	サイトカインの免疫複合体
FR2686087A1 (fr)	1992-01-13	1993-07-16	Inst Nat Sante Rech Med	Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US20030235587A1 (en) *	1998-08-07	2003-12-25	Feuerstein Giora Z.	Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6623960B1 (en) *	1999-02-12	2003-09-23	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
BR0015872A (pt) *	2000-05-15	2004-08-03	Smithkline Beecham Corp	Agentes antitrombóticos
EP1340088B1 (en)	2000-11-17	2007-01-17	University Of Rochester	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002327164A1 (en)	2001-01-29	2002-12-09	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20080138837A1 (en) *	2004-07-19	2008-06-12	Robert Greenfield	Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7780963B2 (en) *	2004-10-25	2010-08-24	Merck & Co., Inc.	Anti-ADDL antibodies and uses thereof
US7859456B2 (en)	2006-10-10	2010-12-28	Sirf Technology Holdings, Inc.	Method of mixed data assisted and non data assisted navigation signal acquisition, tracking and reacquisition
CA2685015A1 (en) *	2007-04-23	2008-11-06	Schering Corporation	Anti-mdl-1 antibodies
HUE046564T2 (hu)	2007-11-21	2020-03-30	Univ Oregon Health & Science	XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
US20110159006A1 (en)	2008-06-19	2011-06-30	Erik Hack	Use of anti-factor xi antibodies for prevention of thrombus formation
WO2010065275A1 (en)	2008-11-25	2010-06-10	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
BR112012030177B1 (pt)	2010-05-27	2019-08-27	Merck Sharp & Dohme	composto ativador da guanilato ciclase solúvel, e, composição farmacêutica
EP2687210A1 (de)	2010-06-25	2014-01-22	Bayer Intellectual Property GmbH	Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
JP6114189B2 (ja)	2010-07-09	2017-04-12	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
CN103619845B (zh)	2011-04-21	2016-08-17	拜耳知识产权有限责任公司	氟烷基取代的吡唑并吡啶及其用途
CA2834901A1 (en)	2011-05-06	2012-11-15	Bayer Intellectual Property Gmbh	Substituted imidazopyridines and imidazopyridazines and the use thereof
KR20140074912A (ko)	2011-09-01	2014-06-18	에프. 호프만-라 로슈 아게	피롤로피라진 키나아제 억제제
EP2751106B1 (de)	2011-09-02	2017-10-18	Bayer Intellectual Property GmbH	Substituierte annellierte pyrimidine und ihre verwendung
WO2013167669A1 (en)	2012-05-10	2013-11-14	Bayer Pharma Aktiengesellschaft	Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

2008
- 2008-11-21 HU HUE15189714A patent/HUE046564T2/hu unknown
- 2008-11-21 PT PT151897147T patent/PT3002298T/pt unknown
- 2008-11-21 EP EP15189714.7A patent/EP3002298B1/en not_active Revoked
- 2008-11-21 JP JP2010535088A patent/JP2011504371A/ja not_active Withdrawn
- 2008-11-21 ES ES08852770.0T patent/ES2566963T3/es active Active
- 2008-11-21 WO PCT/US2008/084336 patent/WO2009067660A2/en not_active Ceased
- 2008-11-21 AU AU2008326348A patent/AU2008326348B2/en not_active Ceased
- 2008-11-21 EP EP08852770.0A patent/EP2222707B1/en not_active Not-in-force
- 2008-11-21 LT LT15189714T patent/LT3002298T/lt unknown
- 2008-11-21 CA CA2705851A patent/CA2705851C/en not_active Expired - Fee Related
- 2008-11-21 ES ES15189714T patent/ES2755376T3/es active Active
- 2008-11-21 US US12/744,037 patent/US8236316B2/en active Active
- 2008-11-21 SI SI200832100T patent/SI3002298T1/sl unknown
- 2008-11-21 PL PL15189714T patent/PL3002298T3/pl unknown
- 2008-11-21 DK DK08852770.0T patent/DK2222707T3/en active
- 2008-11-21 DK DK15189714T patent/DK3002298T3/da active
2012
- 2012-04-13 US US13/446,320 patent/US8399648B2/en active Active
2013
- 2013-03-04 US US13/783,952 patent/US20130171144A1/en not_active Abandoned
2014
- 2014-04-01 US US14/242,692 patent/US9125895B2/en active Active
2015
- 2015-07-27 US US14/809,551 patent/US9636399B2/en active Active
2017
- 2017-03-27 US US15/470,758 patent/US20170204195A1/en not_active Abandoned
2018
- 2018-07-30 US US16/049,141 patent/US10577428B2/en active Active
2019
- 2019-11-05 HR HRP20191999TT patent/HRP20191999T1/hr unknown
- 2019-11-06 CY CY20191101163T patent/CY1122270T1/el unknown

Also Published As

Publication number	Publication date
US20170204195A1 (en)	2017-07-20
DK3002298T3 (da)	2019-10-28
WO2009067660A2 (en)	2009-05-28
HK1223114A1 (en)	2017-07-21
US10577428B2 (en)	2020-03-03
DK2222707T3 (en)	2016-04-11
ES2566963T3 (es)	2016-04-18
CY1122270T1 (el)	2020-11-25
PL3002298T3 (pl)	2020-03-31
AU2008326348A1 (en)	2009-05-28
HRP20191999T1 (hr)	2020-02-07
US8399648B2 (en)	2013-03-19
SI3002298T1 (sl)	2019-12-31
EP3002298B1 (en)	2019-08-28
US9636399B2 (en)	2017-05-02
AU2008326348B2 (en)	2014-01-30
US20130171144A1 (en)	2013-07-04
CA2705851A1 (en)	2009-05-28
US9125895B2 (en)	2015-09-08
US20150322163A1 (en)	2015-11-12
EP3002298A1 (en)	2016-04-06
US20120276112A1 (en)	2012-11-01
ES2755376T3 (es)	2020-04-22
US8236316B2 (en)	2012-08-07
LT3002298T (lt)	2019-12-10
US20180355057A1 (en)	2018-12-13
US20140322219A1 (en)	2014-10-30
JP2011504371A (ja)	2011-02-10
HUE046564T2 (hu)	2020-03-30
EP2222707A2 (en)	2010-09-01
WO2009067660A3 (en)	2009-07-09
US20110020349A1 (en)	2011-01-27
EP2222707B1 (en)	2016-01-06
CA2705851C (en)	2016-11-01

Publication	Publication Date	Title
HUE046564T2 (hu)	2020-03-30	XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
IL266039A (en)	2019-06-30	Anti-factor D antibodies of human origin and their uses
HRP20181969T1 (hr)	2019-02-08	Humanizirana protutijela protiv čimbenika d i njihova upotreba
EP2021029A4 (en)	2010-01-06	HUMANIZED FC RIB SPECIFIC ANTIBODIES AND METHOD FOR THEIR USE
IL200610A0 (en)	2010-05-17	Human monoclonal anti-ip-10 antibodies and uses thereof
PL2594586T3 (pl)	2015-02-27	Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania
IL195573A0 (en)	2011-08-01	Fc??RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2347038A4 (en)	2013-06-12	METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
IL248723B (en)	2018-03-29	Specific antibodies against the bcr complex and methods of using them
HUE042940T2 (hu)	2019-07-29	Anti-FXI antitestek és alkalmazási eljárások
IL196550A0 (en)	2011-08-01	Anti-il-6 monoclonal antibodies and uses thereof
PT2185719E (pt)	2014-02-20	Anticorpos anti-rantes e processos para a sua utilização
ZA201101651B (en)	2012-06-27	Anti-notch2 antibodies and methods of use
EP2077325A4 (en)	2012-04-11	MONOCLONAL ANTIBODY AND ITS USE
EP2540742A4 (en)	2014-02-12	MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF